Endogenous indoleamine 2,3-dioxygenase activity reduces local inflammatory cell numbers Source: Annual Congress 2008 - Basic science in asthma and COPD II Year: 2008
Indoleamine 2,3-dioxygenase in lung allograft tolerance Source: Annual Congress 2009 - Human and experimental lung transplantation: novel findings Year: 2009
Indoleamine 2,3-dioxygenase 1 (IDO1) activity arrests the apoptosis of Mycobacterium tuberculosis (M. tuberculosis)-infected macrophages Source: Virtual Congress 2021 – Immunological and molecular characterisation of tuberculosis disease and infection Year: 2021
Indoleamine 2,3-dioxygenase-1 (IDO1) activity protects M. tuberculosis in macrophages from antibiotics Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019
Airway epithelial expression of indoleamine 2,3-dioxygenase and resolution of local inflammatory cells Source: Annual Congress 2007 - The best of airway epithelial cells Year: 2007
Transcriptional expression of human telomerase reverse transcriptase (hTERT) and indoleamine 2,3-dioxygenase (IDO) in non-small cell lung cancer Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010
Correlation of neutrophil CD64 expression with disease severity in sepsis Source: Annual Congress 2004 - Mechanisms and diagnosis of pulmonary infection diseases in the ICU Year: 2004
The increased production level of 15 cytokines associated with tuberculosis severity and patients’ responsiveness to therapy. Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019
Increased LIR-1 expression precedes serum cytomegalovirus detection and diagnosis of CMV disease in lung transplant recipients Source: Eur Respir J 2002; 20: Suppl. 38, 347s Year: 2002
Increased TNFα production in whole blood is associated with disease severity in COPD Source: Eur Respir J 2002; 20: Suppl. 38, 497s Year: 2002
Chitotriosidase: a marker and modulator of lung disease Source: Eur Respir Rev, 29 (156) 190143; 10.1183/16000617.0143-2019 Year: 2020
Down-regulation of pro-inflammatory response genes of circulating leukocytes in ICU patients with severe pneumonia meeting criteria of systemic inflammatory response syndrome (SIRS) Source: Eur Respir J 2003; 22: Suppl. 45, 543s Year: 2003
Systemic cytokine levels in community-acquired pneumonia and their association with disease severity Source: Eur Respir J 2002; 20: 990-995 Year: 2002
Frequency, severity and risk factors of drug-induced liver injury during treatment of new tuberculosis patients Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Upregulation of myeloid derived suppressor cells (MDSCs) in chronic obstructive pulmonary disease and its relationship with disease severity Source: Annual Congress 2012 - Asthma and COPD: understanding through mechanisms Year: 2012
Enhanced expression of proinflammatory cytokine (IL-18) and its receptor in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 551s Year: 2006
Elevated circulating CTLA-4 level in patients with COPD is related to systemic inflammation and disease severity Source: Annual Congress 2013 –COPD: markers and inflammation Year: 2013
Measurement of serum total antioxidant status in patients with community acquired pneumonia: correlation with the severity of the disease Source: Eur Respir J 2002; 20: Suppl. 38, 283s Year: 2002
Neutrophil CD64 expression: a sensitive early marker of severity in sepsis Source: Eur Respir J 2005; 26: Suppl. 49, 221s Year: 2005
Neutrophil CD64 versus Neutrophil/Lymphocyte ratio (NLR) as markers predicting in-hospital outcome in acute exacerbation of COPD Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017